Clinical Trial Update: A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189 in Healthy Adults 18 to 30 Years of Age [Phase 1]

View source ↗

Summary

Phase 1 clinical trial update for an Epstein-Barr virus vaccine candidate, mRNA-1189, currently recruiting in healthy adults.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Epstein-barr Virus Infection

Drugs mentioned

• mRNA-1189

Snippet

Sponsor: ModernaTX, Inc. | Conditions: Epstein-Barr Virus | Phase 1 | Status: RECRUITING